Brief: Endra Life Sciences' Taeus De Novo Submission Advances To Next Stage Of Review With FDA
30/08/2023 13:09
Aug 30 (Reuters) - ENDRA Life Sciences Inc NDRA.O :
* ENDRA LIFE SCIENCES' TAEUS DE NOVO SUBMISSION ADVANCES TO
NEXT
STAGE OF REVIEW WITH FDA
Source text for Eikon: ID:nBwx6kd8a
Further company coverage: NDRA.O
Recent news on ENDRA Life Sciences
See all newsBrief: ENDRA Life Sciences - Enters First Amendment To Merger Agreement On October 1, 2026 - SEC Filing
ENDRA Life Sciences posts Q2 profit on digital asset gains ahead of merger
Endra Life Sciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Endra Life Sciences Inc Expected To Post A Loss Of 84 Cents A Share: Earnings Preview
Brief: ASP Isotopes Announces Proposed Merger Of Noble Africa With Endra Life Sciences